Effects of immunomodulators on acute Trypanosoma cruzi infection in mice

Helieh S. Oz, Walter T. Hughes, Elaine K. Thomas, Craig J. McClain

Research output: Contribution to journalArticle

Abstract

Background: Patients who recover from acute trypanosomiasis may succumb to chronic Chagas' disease later in life due to age related immunosuppression, immune system disorders such as AIDS, or during periods of immunosuppressive therapy for organ transplantation. In this study, effects of immunomodulators with diverse properties were examined on the course of an acute and lethal Trypanosoma cruzi infection. Material/Methods: ICR (Swiss) mice inoculated with Tulahuen (lethal) strain of T. cruzi were treated with 6 different immunomodulators and the course of infection was studied. Results: Tacrolimus (FK-506) and dexamethasone increased parasitemia in mice when compared to infected untreated animals. Mycophenolate mofetil (RS-61443) and recombinant interleukin-15 (IL-15) treatment decreased the number of parasites but had no effect on animal survival. In contrast, compound L-685-818 (tacrolimus analog) and CD40 ligand (CD40L), provided protection against lethal infection. Mice that survived initial infection were all protected against reinfection. Conclusion: This study demonstrates the dangers of immunosuppression with tacrolimus and dexamethasone in T. cruzi infected subjects. While mycophenolate did not exacerbate the infection, our data suggest potential therapeutic applications for L-685-818 and CD40 ligand in trypanosomiasis.

Original languageEnglish (US)
JournalMedical Science Monitor
Volume8
Issue number6
StatePublished - 2002
Externally publishedYes

Fingerprint

Trypanosoma cruzi
Immunologic Factors
Tacrolimus
Mycophenolic Acid
Infection
CD40 Ligand
Trypanosomiasis
Immunosuppression
Dexamethasone
Interleukin-15
Inbred ICR Mouse
Parasitemia
Chagas Disease
Immune System Diseases
Organ Transplantation
Immunosuppressive Agents
Immune System
Parasites
Acquired Immunodeficiency Syndrome
Chronic Disease

Keywords

  • CD40L
  • Immunomodulators
  • L-685-818
  • Mycophenolate
  • T. cruzi
  • Tacrolimus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Oz, H. S., Hughes, W. T., Thomas, E. K., & McClain, C. J. (2002). Effects of immunomodulators on acute Trypanosoma cruzi infection in mice. Medical Science Monitor, 8(6).

Effects of immunomodulators on acute Trypanosoma cruzi infection in mice. / Oz, Helieh S.; Hughes, Walter T.; Thomas, Elaine K.; McClain, Craig J.

In: Medical Science Monitor, Vol. 8, No. 6, 2002.

Research output: Contribution to journalArticle

Oz, HS, Hughes, WT, Thomas, EK & McClain, CJ 2002, 'Effects of immunomodulators on acute Trypanosoma cruzi infection in mice', Medical Science Monitor, vol. 8, no. 6.
Oz, Helieh S. ; Hughes, Walter T. ; Thomas, Elaine K. ; McClain, Craig J. / Effects of immunomodulators on acute Trypanosoma cruzi infection in mice. In: Medical Science Monitor. 2002 ; Vol. 8, No. 6.
@article{1530fc72827145c4af356f4c2d16a144,
title = "Effects of immunomodulators on acute Trypanosoma cruzi infection in mice",
abstract = "Background: Patients who recover from acute trypanosomiasis may succumb to chronic Chagas' disease later in life due to age related immunosuppression, immune system disorders such as AIDS, or during periods of immunosuppressive therapy for organ transplantation. In this study, effects of immunomodulators with diverse properties were examined on the course of an acute and lethal Trypanosoma cruzi infection. Material/Methods: ICR (Swiss) mice inoculated with Tulahuen (lethal) strain of T. cruzi were treated with 6 different immunomodulators and the course of infection was studied. Results: Tacrolimus (FK-506) and dexamethasone increased parasitemia in mice when compared to infected untreated animals. Mycophenolate mofetil (RS-61443) and recombinant interleukin-15 (IL-15) treatment decreased the number of parasites but had no effect on animal survival. In contrast, compound L-685-818 (tacrolimus analog) and CD40 ligand (CD40L), provided protection against lethal infection. Mice that survived initial infection were all protected against reinfection. Conclusion: This study demonstrates the dangers of immunosuppression with tacrolimus and dexamethasone in T. cruzi infected subjects. While mycophenolate did not exacerbate the infection, our data suggest potential therapeutic applications for L-685-818 and CD40 ligand in trypanosomiasis.",
keywords = "CD40L, Immunomodulators, L-685-818, Mycophenolate, T. cruzi, Tacrolimus",
author = "Oz, {Helieh S.} and Hughes, {Walter T.} and Thomas, {Elaine K.} and McClain, {Craig J.}",
year = "2002",
language = "English (US)",
volume = "8",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of immunomodulators on acute Trypanosoma cruzi infection in mice

AU - Oz, Helieh S.

AU - Hughes, Walter T.

AU - Thomas, Elaine K.

AU - McClain, Craig J.

PY - 2002

Y1 - 2002

N2 - Background: Patients who recover from acute trypanosomiasis may succumb to chronic Chagas' disease later in life due to age related immunosuppression, immune system disorders such as AIDS, or during periods of immunosuppressive therapy for organ transplantation. In this study, effects of immunomodulators with diverse properties were examined on the course of an acute and lethal Trypanosoma cruzi infection. Material/Methods: ICR (Swiss) mice inoculated with Tulahuen (lethal) strain of T. cruzi were treated with 6 different immunomodulators and the course of infection was studied. Results: Tacrolimus (FK-506) and dexamethasone increased parasitemia in mice when compared to infected untreated animals. Mycophenolate mofetil (RS-61443) and recombinant interleukin-15 (IL-15) treatment decreased the number of parasites but had no effect on animal survival. In contrast, compound L-685-818 (tacrolimus analog) and CD40 ligand (CD40L), provided protection against lethal infection. Mice that survived initial infection were all protected against reinfection. Conclusion: This study demonstrates the dangers of immunosuppression with tacrolimus and dexamethasone in T. cruzi infected subjects. While mycophenolate did not exacerbate the infection, our data suggest potential therapeutic applications for L-685-818 and CD40 ligand in trypanosomiasis.

AB - Background: Patients who recover from acute trypanosomiasis may succumb to chronic Chagas' disease later in life due to age related immunosuppression, immune system disorders such as AIDS, or during periods of immunosuppressive therapy for organ transplantation. In this study, effects of immunomodulators with diverse properties were examined on the course of an acute and lethal Trypanosoma cruzi infection. Material/Methods: ICR (Swiss) mice inoculated with Tulahuen (lethal) strain of T. cruzi were treated with 6 different immunomodulators and the course of infection was studied. Results: Tacrolimus (FK-506) and dexamethasone increased parasitemia in mice when compared to infected untreated animals. Mycophenolate mofetil (RS-61443) and recombinant interleukin-15 (IL-15) treatment decreased the number of parasites but had no effect on animal survival. In contrast, compound L-685-818 (tacrolimus analog) and CD40 ligand (CD40L), provided protection against lethal infection. Mice that survived initial infection were all protected against reinfection. Conclusion: This study demonstrates the dangers of immunosuppression with tacrolimus and dexamethasone in T. cruzi infected subjects. While mycophenolate did not exacerbate the infection, our data suggest potential therapeutic applications for L-685-818 and CD40 ligand in trypanosomiasis.

KW - CD40L

KW - Immunomodulators

KW - L-685-818

KW - Mycophenolate

KW - T. cruzi

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=0036596094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036596094&partnerID=8YFLogxK

M3 - Article

C2 - 12070425

AN - SCOPUS:0036596094

VL - 8

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 6

ER -